|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
28,040,000 |
Market
Cap: |
40.66(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$1.03 - $3.86 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Corvus Pharmaceuticals is a clinical stage biopharmaceutical company focused on the development of immune modulator product candidates to treat solid cancers, T-cell lymphomas, autoimmune diseases and infectious diseases. Co.'s lead product candidate is mupadolimab, a humanized monoclonal antibody that is designed to react with a specific site on CD73. Co.'s next product candidate, CPI-818, is a selective, covalent inhibitor of ITK and is in a multi-center Phase 1/1b clinical trial in patients with various malignant T-cell lymphomas. Co.'s third product candidate, ciforadenant, is an oral, small molecule antagonist of the A2A receptor for adenosine.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
10,000 |
184,890 |
Total Buy Value |
$0 |
$0 |
$24,500 |
$162,021 |
Total People Bought |
0 |
0 |
1 |
4 |
Total Buy Transactions |
0 |
0 |
1 |
12 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Grais Linda S |
|
|
2023-05-15 |
4 |
B |
$2.45 |
$24,500 |
D/D |
10,000 |
10,000 |
0.01 |
-41% |
|
Jones William Benton |
See Remarks |
|
2022-12-20 |
4 |
B |
$0.79 |
$15,800 |
D/D |
20,000 |
133,773 |
2.74 |
32% |
|
Lea Leiv |
Chief Financial Officer |
|
2022-12-14 |
4 |
B |
$0.84 |
$3,364 |
I/I |
4,000 |
133,238 |
1.91 |
28% |
|
Miller Richard A Md |
President and CEO |
|
2022-12-14 |
4 |
B |
$0.78 |
$7,812 |
I/I |
10,000 |
1,490,119 |
2.58 |
28% |
|
Lea Leiv |
Chief Financial Officer |
|
2022-12-13 |
4 |
B |
$0.74 |
$22,275 |
I/I |
30,000 |
129,238 |
1.99 |
31% |
|
Miller Richard A Md |
President and CEO |
|
2022-12-13 |
4 |
B |
$0.74 |
$37,015 |
I/I |
50,000 |
1,480,119 |
2.66 |
31% |
|
Miller Richard A Md |
President and CEO |
|
2022-09-28 |
4 |
B |
$0.76 |
$19,070 |
I/I |
25,000 |
1,394,405 |
2.58 |
7% |
|
Miller Richard A Md |
President and CEO |
|
2022-09-20 |
4 |
B |
$0.81 |
$16,253 |
I/I |
20,000 |
1,369,405 |
2.58 |
4% |
|
Miller Richard A Md |
President and CEO |
|
2022-06-27 |
4 |
B |
$1.00 |
$4,985 |
I/I |
5,000 |
1,349,405 |
2.58 |
-22% |
|
Miller Richard A Md |
President and CEO |
|
2022-06-24 |
4 |
B |
$1.03 |
$5,150 |
I/I |
5,000 |
1,344,405 |
2.58 |
-1% |
|
Miller Richard A Md |
President and CEO |
|
2022-06-06 |
4 |
B |
$1.01 |
$899 |
I/I |
890 |
1,339,405 |
2.58 |
-11% |
|
Miller Richard A Md |
President and CEO |
|
2022-06-02 |
4 |
B |
$0.97 |
$4,898 |
I/I |
5,000 |
1,338,515 |
2.58 |
-6% |
|
Miller Richard A Md |
President and CEO |
|
2022-03-31 |
4 |
B |
$1.64 |
$24,534 |
I/I |
15,000 |
1,333,515 |
2.58 |
-47% |
|
Miller Richard A Md |
President and CEO |
|
2022-03-17 |
4 |
B |
$1.59 |
$7,950 |
I/I |
5,000 |
1,318,515 |
2.58 |
-44% |
|
Lea Leiv |
Chief Financial Officer |
|
2022-03-17 |
4 |
B |
$1.65 |
$22,899 |
I/I |
13,878 |
99,238 |
1.99 |
-44% |
|
Lea Leiv |
Chief Financial Officer |
|
2022-03-16 |
4 |
B |
$1.54 |
$54,146 |
I/I |
35,160 |
85,360 |
1.99 |
-44% |
|
Miller Richard A Md |
President and CEO |
|
2022-03-15 |
4 |
B |
$1.47 |
$36,650 |
I/I |
25,000 |
1,313,515 |
2.66 |
-36% |
|
Ecor1 Capital, Llc |
10% Owner |
|
2021-10-01 |
4 |
S |
$4.96 |
$9,928,800 |
I/I |
(2,000,000) |
81,077 |
|
60% |
|
Ecor1 Capital, Llc |
10% Owner |
|
2021-09-30 |
4 |
S |
$5.04 |
$15,131,100 |
I/I |
(3,000,000) |
2,081,077 |
|
59% |
|
Ecor1 Capital, Llc |
10% Owner |
|
2021-09-22 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
5,081,077 |
|
-77% |
|
Thompson Peter A |
Director |
|
2021-09-20 |
4 |
S |
$6.09 |
$6,757,732 |
I/I |
(1,109,644) |
6,943,654 |
|
71% |
|
Orbimed Capital Gp V Llc |
Director |
|
2021-09-20 |
4 |
S |
$6.09 |
$6,757,732 |
I/I |
(1,109,644) |
6,943,654 |
|
71% |
|
Miller Richard A Md |
President and CEO |
|
2021-08-20 |
4 |
B |
$1.93 |
$19,254 |
I/I |
10,000 |
1,288,515 |
2.58 |
26% |
|
Miller Richard A Md |
President and CEO |
|
2021-05-04 |
4 |
B |
$2.80 |
$99,999 |
D/D |
35,714 |
35,714 |
2.81 |
-12% |
|
Orbimed Capital Gp V Llc |
Director |
|
2021-02-17 |
4 |
B |
$3.50 |
$4,499,999 |
I/I |
1,285,714 |
8,053,298 |
2.25 |
-23% |
|
112 Records found
|
|
Page 1 of 5 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|